2020
Cost-effectiveness of post-treatment follow-up examinations and secondary prevention of tuberculosis in a high-incidence setting: a model-based analysis
Marx FM, Cohen T, Menzies NA, Salomon JA, Theron G, Yaesoubi R. Cost-effectiveness of post-treatment follow-up examinations and secondary prevention of tuberculosis in a high-incidence setting: a model-based analysis. The Lancet Global Health 2020, 8: e1223-e1233. PMID: 32827484, PMCID: PMC7549318, DOI: 10.1016/s2214-109x(20)30227-8.Peer-Reviewed Original ResearchConceptsIsoniazid preventive therapySecondary preventive therapyHigh-incidence settingsPost-treatment followPreventive therapyTuberculosis controlTuberculosis incidenceTreatment completionTuberculosis case findingOverall disease burdenHigh tuberculosis incidenceTuberculosis-endemic settingHigh-incidence communityFirst yearHealth system costsRecurrent tuberculosisSecondary preventionAnnual followTuberculosis treatmentDisease burdenHigh riskCase findingSingle followSuburban Cape TownPreventive interventions
2019
Notification of relapse and other previously treated tuberculosis in the 52 health districts of South Africa
Marx F, Cohen T, Lombard C, Hesseling A, Dlamini S, Beyers N, Naidoo P. Notification of relapse and other previously treated tuberculosis in the 52 health districts of South Africa. The International Journal Of Tuberculosis And Lung Disease 2019, 23: 891-899. PMID: 31533878, DOI: 10.5588/ijtld.18.0609.Peer-Reviewed Original ResearchConceptsSouth African health districtTB casesCase notification ratesHealth districtTB burdenNotification ratesHigh case notification ratesHIV co-infection rateHuman immunodeficiency virus (HIV) prevalenceTB case notification ratesAntenatal HIV prevalenceSecondary preventive therapyDrug-susceptible tuberculosisNew TB casesCo-infection rateTreatment history informationPreventive therapyMultivariable analysisHIV prevalenceSouth African districtPatient categoriesRelapseTuberculosisTreatment monitoringVirus prevalence
2009
Patients with prior coronary artery bypass grafting have a poor outcome after myocardial infarction: an analysis of the VALsartan in acute myocardial iNfarcTion trial (VALIANT)
Berry C, Pieper KS, White HD, Solomon SD, Van de Werf F, Velazquez EJ, Maggioni AP, Califf RM, Pfeffer MA, McMurray JJ. Patients with prior coronary artery bypass grafting have a poor outcome after myocardial infarction: an analysis of the VALsartan in acute myocardial iNfarcTion trial (VALIANT). European Heart Journal 2009, 30: 1450-1456. PMID: 19346225, DOI: 10.1093/eurheartj/ehp102.Peer-Reviewed Original ResearchConceptsPrior CABG patientsCoronary artery bypassMyocardial infarctionCABG patientsPrior CABGHeart failureArtery bypassNon-Q-wave myocardial infarctionPrior coronary artery bypassAcute Myocardial Infarction trialPrimary percutaneous coronary interventionKaplan-Meier ratesSecondary preventive therapyWorse clinical profileMyocardial Infarction trialVentricular systolic dysfunctionHigh-risk patientsPercutaneous coronary interventionAcute myocardial infarctionNumber of patientsNon-fatal outcomesHospital presentationLess aspirinMore comorbiditiesCardiovascular deathThe Adherence eValuation After Ischemic Stroke Longitudinal (AVAIL) Registry: Design, rationale, and baseline patient characteristics
Bushnell C, Zimmer L, Schwamm L, Goldstein L, Clapp-Channing N, Harding T, Drew L, Zhao X, Peterson E. The Adherence eValuation After Ischemic Stroke Longitudinal (AVAIL) Registry: Design, rationale, and baseline patient characteristics. American Heart Journal 2009, 157: 428-435.e2. PMID: 19249411, DOI: 10.1016/j.ahj.2008.11.002.Peer-Reviewed Original ResearchConceptsIschemic stroke Longitudinal (AVAIL) registryTransient ischemic attackIschemic attackRecurrent strokePrevention medicationsLongitudinal registryAdherence evaluationSecondary preventive therapyBaseline patient characteristicsModified Rankin scoreSecondary prevention measuresMedication-taking behaviorSystem-level barriersLevel of adherenceFuture strokeCardiovascular eventsRankin scoreVascular eventsAcute hospitalizationHospital dischargePatient characteristicsPreventive therapySecondary outcomesMedication usePrimary outcome
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply